Phase I study of bevacizumab and temsirolimus combination therapy in advanced malignancies: safety, efficacy, and ovarian cancer expansion
Combination therapy showed acceptable safety and modest activity. Molecular and imaging findings were exploratory and limited. These preliminary observations could inform future biomarker studies. (ClinicalTrials.gov Identifier: NCT01552434).
Authors
- Hung Le (ORCID: https://orcid.org/0009-0007-8886-926X)
- R. Jason Stafford (ORCID: https://orcid.org/0000-0003-4091-8417)
- David S. Hong (ORCID: https://orcid.org/0000-0001-8721-1609)
- Shannon N. Westin (ORCID: https://orcid.org/0000-0002-1922-0156)
- Sarina A. Piha‐Paul (ORCID: https://orcid.org/0000-0001-9455-1660)
- Jordi Rodón (ORCID: https://orcid.org/0000-0001-6467-3632)
- John M. Slopis (ORCID: https://orcid.org/0000-0002-1847-0583)
- Apostolia Maria Tsimberidou (ORCID: https://orcid.org/0000-0003-2713-233X)
- Siqing Fu (ORCID: https://orcid.org/0000-0002-1933-0419)
- Chaan S. Ng (ORCID: https://orcid.org/0000-0001-9261-7021)
- Funda Meric‐Bernstam (ORCID: https://orcid.org/0000-0001-6816-6072)
- George R. Blumenschein (ORCID: https://orcid.org/0000-0002-9606-8194)
- Lei Kang (ORCID: https://orcid.org/0000-0001-8729-4547)
- Anil K. Sood (ORCID: https://orcid.org/0000-0003-4242-1762)
- Emily Thompson (ORCID: https://orcid.org/0009-0009-6178-1393)
- Chieh Tseng
- A. Niang
Institutions
- The University of Texas MD Anderson Cancer Center (US)
Publication Details
- Journal
- The Oncologist
- Published
- 2025-12-11
- DOI
- https://doi.org/10.1093/oncolo/oyaf413
- Primary Topic
- Ovarian cancer diagnosis and treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Institutes of Health
- University of Texas MD Anderson Cancer Center